Millennium Management’s Atara Biotherapeutics ATRA Stock Holding History

Millennium Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-400	Closed	-$196K	–	5894
2020 Q4	$196K	Buy	+400	New	+$185K	﹤0.01%	4818
2019 Q2	–	Sell	-572	Closed	-$568K	–	4035
2019 Q1	$568K	Buy	+572	New	+$531K	﹤0.01%	3189
2018 Q3	–	Sell	-4,000	Closed	-$3.67M	–	3873
2018 Q2	$3.67M	Buy	+4,000	New	+$4.3M	﹤0.01%	2004

Other funds holding ATRA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's ATRA Position: Q1 2026 in Review

Millennium Management opened a new position in Atara Biotherapeutics (ATRA) in Q1 2026: 47,689 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #5130 among its holdings. This is a return to the name: Millennium Management previously reported a position in ATRA as recently as Q4 2024.

Millennium Management first reported a position in ATRA in Q4 2015 and has held it in 28 quarters since. The position peaked at $6.38M in Q1 2019. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

Millennium Management held 47,689 shares of Atara Biotherapeutics worth $226K as of Q1 2026.
Atara Biotherapeutics was a new Millennium Management position in Q1 2026.
Atara Biotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5130 holding.
Millennium Management first reported a position in Atara Biotherapeutics in Q4 2015 and has held it in 28 quarters since.
Millennium Management's Atara Biotherapeutics position peaked at $6.38M in Q1 2019.
33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.